Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
Enlivex Therapeutics announced that the Japan Patent Office has allowed a patent application for ALLOCETRA, their immunotherapy candidate. The patent will provide intellectual property protection for its use and pharmaceutical compositions. The company anticipates the patent to be issued in Q3 2020. ALLOCETRA is designed to target serious clinical indications, including organ dysfunction related to sepsis and COVID-19, as well as modulating the tumor microenvironment for solid tumors. Enlivex focuses on developing allogeneic drugs for immune system rebalancing.
- The Japan Patent Office has allowed a patent for ALLOCETRA, enhancing intellectual property protection.
- ALLOCETRA targets critical medical needs such as organ dysfunction and acute multiple organ failure.
- None.
Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRATM, the company’s immunotherapy product candidate. Upon issuance, the new patent will provide additional intellectual property protection around methods of using ALLOCETRATM and pharmaceutical compositions comprising the same. The company expects the new patent to issue in Japan during the third quarter of 2020.
ABOUT ALLOCETRATM
ALLOCETRATM was designed to provide a novel immunotherapeutic mechanism of action that targets life-threatening clinical indications that are defined as “unmet medical needs”. Such clinical indications include organ dysfunction and acute multiple organ failure associated with sepsis and COVID-19, as well as solid tumors, which can be treated via modulation of the tumor microenvironment.
ABOUT ENLIVEX
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
FAQ
What news did Enlivex Therapeutics announce on June 18, 2020?
What is ALLOCETRA by Enlivex Therapeutics?
When is the patent for ALLOCETRA expected to be issued in Japan?
What are the key applications of ALLOCETRA?
What does Enlivex focus on in its drug development?
